Login / Signup
Semaglutide 2.4 mg: the latest GLP-1RA approved for obesity.
Ricardo Villela
Riccardo Correa
Published in:
Journal of investigative medicine : the official publication of the American Federation for Clinical Research (2022)
Keyphrases
</>
insulin resistance
metabolic syndrome
weight loss
rheumatoid arthritis
high fat diet induced
type diabetes
weight gain
drug administration
disease activity
ankylosing spondylitis
systemic lupus erythematosus
adipose tissue
body mass index
interstitial lung disease
idiopathic pulmonary fibrosis